In the EpiPen case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Mylan’s EpiPen, an epinephrine auto-injector used to treat anaphylaxis (i.e. allergic reactions). The complaint alleges that Mylan paid bribes and kickbacks to pharmacy benefit managers CVS/Caremark, Express Scripts, and OptumRx to engage in anticompetitive conduct that led to artificially inflated prices for the $1 billion a year, life-saving drug. Claims have been asserted under the Sherman Act and RICO statutes.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 03/29/2020
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Joseph T. Lukens email@example.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn firstname.lastname@example.org Phone (215) 277-5770 Fax (215) 277-5771